Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.52 |
| ▸ | TACR1 | P25103 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8472276 | 0.85 | SLC6A2 (0.62) | CYP2D6SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL30330150 | 0.81 | TACR1 (0.46) | CYP2D6SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL15719175 | 0.80 | CYP2D6 (0.62) | CYP2D6CYP19A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL30330305 | 0.80 | CYP2D6 (0.62) | CYP2D6CYP19A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11623491 | 0.79 | CYP2D6 (0.57) | CYP2D6CYP19A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14593323 | 0.79 | CYP2D6 (0.57) | CYP2D6CYP19A1SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL17107338 | 0.78 | CYP2D6 (0.60) | CYP2D6CYP19A1SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL23532325 | 0.78 | CYP2D6 (0.55) | CYP2D6CYP19A1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL13476491 | 0.77 | SLC6A4 (0.57) | CYP2D6SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL11627158 | 0.77 | CYP2D6 (0.54) | CYP2D6CYP19A1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | CYP2D6 1085/4885CYP19A1 375/4885SLC6A4 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.